spironolactone has been researched along with Experimental Hepatoma in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "25% salt in drinking water improved body weight reduction associated with sodium and water retention in hepatocellular carcinoma rats, which was suppressed by treatment with spironolactone, a mineralocorticoid receptor antagonist." | 4.12 | Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. ( Kidoguchi, S; Kitada, K; Kittikulsuth, W; Kobara, H; Masaki, T; Nakajima, K; Nakano, D; Nishiyama, A; Ohsaki, H; Takahashi, K; Titze, J; Yokoo, T, 2022) |
| " We determined the effects of SR alone or in combination with the antioxidant α-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjected to a two-stage hepatocarcinogenesis model." | 1.48 | Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation. ( Eguchi, A; Hayashi, SM; Kawashima, M; Kimura, M; Koyanagi, M; Makino, E; Maronpot, RR; Mizukami, S; Murayama, H; Nagahara, R; Nakamura, M; Ohtsuka, R; Shibutani, M; Takahashi, N; Yoshida, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kidoguchi, S | 1 |
| Kitada, K | 1 |
| Nakajima, K | 1 |
| Nakano, D | 1 |
| Ohsaki, H | 1 |
| Kittikulsuth, W | 1 |
| Kobara, H | 1 |
| Masaki, T | 1 |
| Yokoo, T | 1 |
| Takahashi, K | 1 |
| Titze, J | 1 |
| Nishiyama, A | 1 |
| Murayama, H | 1 |
| Eguchi, A | 1 |
| Nakamura, M | 1 |
| Kawashima, M | 1 |
| Nagahara, R | 1 |
| Mizukami, S | 1 |
| Kimura, M | 1 |
| Makino, E | 1 |
| Takahashi, N | 1 |
| Ohtsuka, R | 1 |
| Koyanagi, M | 1 |
| Hayashi, SM | 1 |
| Maronpot, RR | 1 |
| Shibutani, M | 1 |
| Yoshida, T | 1 |
| Campen, TJ | 1 |
| Fanestil, DD | 1 |
3 other studies available for spironolactone and Experimental Hepatoma
| Article | Year |
|---|---|
Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats.
Topics: Aldosterone; Animals; Carcinoma, Hepatocellular; Diethylnitrosamine; Liver Neoplasms, Experimental; | 2022 |
Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation.
Topics: Animals; Body Weight; Diet, High-Fat; Drug Therapy, Combination; Fatty Liver; Liver Neoplasms, Exper | 2018 |
Spironolactone: a glucocorticoid agonist or antagonist?
Topics: Adrenalectomy; Animals; Cell Line; Cell Nucleus; Dexamethasone; Enzyme Induction; Liver Neoplasms, E | 1982 |